Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Open Access
- 25 March 2020
- journal article
- review article
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 17 (3), 181-192
- https://doi.org/10.30773/pi.2019.0236
Abstract
Major depressive disorder (MUD) is a serious psychiatric illness that causes functional impairment in many people. While monoaminergic antidepressants have been used to effectively treat MDD, these antidepressants have limitations in that they have delayed onset of action and many patients remain treatment-resistant. Therefore, there is a need to develop antidepressants with a novel target, and researchers have directed their attention to the glutamatergic system. Ketamine, although developed as an anesthetic, has been found to produce an antidepressant effect at sub-anesthetic doses via N-Methyl-D-aspartic acid (NMDA) receptor blockade as well as NMDA receptor-independent pathways. A single infusion of ketamine produced rapid improvement in clinical symptoms to a considerable level and led to the resolution of serious depressive symptoms, including imminent suicidal ideation, in patients with MDD. A series of recent randomized controlled trials have provided a high level of evidence for the therapeutic efficacy of ketamine treatment in MDD and presented new insights on the dose, usage, and route of administration of ketamine as an antidepressant. With this knowledge, it is expected that ketamine treaunent protocols for MDD will be established as a treatment option available in clinical practice. However, long-term safety must be taken into consideration as ketamine has abuse potential and it is associated with psychological side effects such as dissociative or psychotomimetic effects.Keywords
This publication has 117 references indexed in Scilit:
- Open vs. Closed Skill Sports and the Modulation of Inhibitory ControlPLOS ONE, 2013
- A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive DisorderJournal of Clinical Psychopharmacology, 2012
- Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On TrialBiological Psychiatry, 2012
- Distinct Modes of AMPA Receptor Suppression at Developing Synapses by GluN2A and GluN2B: Single-Cell NMDA Receptor Subunit Deletion In VivoNeuron, 2011
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responsesNature, 2011
- Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress ExposureBiological Psychiatry, 2011
- Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disordersNature Reviews Neuroscience, 2010
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA AntagonistsScience, 2010
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar DepressionArchives of General Psychiatry, 2010
- Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzoleMolecular Psychiatry, 2008